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Summary Coronary (artery) spasm plays an important role in the pathogenesis
of ischemic heart disease, including stable angina, unstable angina, myocardial
infarction, and sudden death. The prevalence of coronary spasm differs among
populations, is higher in Japan and Korea than in the Western countries proba-
bly due to genetic as well as environmental factors. Coronary spasm occurs most
often from midnight to early morning and is usually not induced by exercise in the
daytime. The attacks of coronary spasm are associated with either ST segment ele-
vation or depression, or negative U wave on ECG. Patients with multi-vessel coronary
spasm may suffer from lethal arrhythmia, including advanced AV block, ventricular
tachycardia or ﬁbrillation, or even sudden death, and they are often resistant to con-
ventional medical therapy including Ca-channel blockers (CCBs). Endothelial nitric
oxide (NO) activity is reduced andmarkers of oxidative stress are elevated in patients
with coronary spasm. Thrombogenesis is enhanced and plasma levels of hsCRP and
P-selection are elevated in patients with coronary spasm. Thus, patients with coro-
nary spasm have endothelial dysfunction and are suffering from a low-grade chronic
inﬂammation. Polymorphisms of endothelial NO synthase, smoking, and low-grade
inﬂammation are themost important risk factors for coronary spasm. Coronary spasm
is a hyper-contraction of coronary smooth muscle triggered by an increase of intra-
cellular Ca2+ in the presence of an increased Ca2+ sensitivity. It has been shown that
RhoA/ROCK pathway is involved in Ca2+ sensitivity and that the reduced endothe-
lial NO activity results in increased Ca2+ sensitivity through enhanced RhoA/ROCK
pathway. Accordingly, it is possible that in addition to CCBs, RhoA/ROCK pathway
blockers may prove to be useful for the treatment of coronary spasm.
© 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights
reserved.
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a‘CORONARY SPASM—–The hypothesis, once widely
ccepted, that active constriction of the coronary
rteries is the chief mechanism of angina pectoris
s no longer valid.’’
Harrison and Reeves [7, p. 52].
Angina pectoris is caused by transient myocardial
schemia due to an imbalance between myocar-
ial oxygen demand and supply [1,2]. Classical or
table effort angina is characterized by (1) the
ttack is induced by exertion and relieved by rest
r nitroglycerin administration, and (2) the attack
s associated with transient ST segment depres-
ion in the electrocardiogram [1—3]. This form of
ngina has been well known for more than 200
ears since its description by Heberden [4] and
ts pathogenesis has been explained by increased
yocardial oxygen demand in the presence of ﬁxed
rganic stenosis of epicardial coronary arteries
1—3]. This concept was based on the fact that
he majority of patients with angina were found
o have severe and extensive atherosclerotic nar-
owing in their coronary arteries. Beta-adrenergic
locking agents, which reduce myocardial oxygen
emand, have been widely used for the treat-
ent of angina. The efﬁcacy of nitroglycerin has
een attributed chieﬂy to its venodilatatory effect,
hich results in pooling of blood in the venous sys-
em leading to decreased myocardial work rather
a
[
ihan to its direct effect on the coronary arteries
5].
In 1959, Prinzmetal et al. [6] described a new
orm of angina pectoris which differed sharply
rom the classical angina and named it ‘‘variant
orm of angina pectoris.’’ The characteristics of
his syndrome were: the attack associated with
T segment elevation on ECG occurred at rest
nd was not induced by exertion. However, this
yndrome drew little attention among the car-
iologists at that time probably because it was
sually not induced by exercise in the daytime
nd the concept of increased myocardial oxygen
emand as a cause of angina pectoris prevailed
1,7].
With the introduction of coronary angiography
y Sones and Shirey in 1959 [8] and its widespread
se, spasm of an epicardial coronary artery or
oronary spasm was documented angiographically
uring the attack of variant angina at several insti-
utions in the early 1970s [9—11]. Thus, coronary
pasm was established as the cause of variant
ngina [10—12]. With the introduction of ambu-
atory ECG monitoring for myocardial ischemia
nd its widespread use, many cases of variant
ngina have been reported, particularly in Japan
13,14].
It is now known that coronary spasm plays an
mportant role in the pathogenesis not only of
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variant angina but also of ischemic heart dis-
ease in general, including effort angina, unstable
angina, acute myocardial infarction and sudden
death [15—18], and thus the postulation of Har-
rison, cited above [7] is no longer valid. Thus,
variant angina is only one aspect of the wide spec-
trum of myocardial ischemic syndromes [15] caused
by coronary spasm. Angina caused by coronary
spasm is now usually called ‘‘coronary (vaso) spas-
tic angina’’ and the name ‘‘variant angina’’ is less
often used [18].
Coronary constriction and spasm
Coronary arteries are able to contract and relax via
various mechanisms. Thus, coronary constriction is
a normal phenomenon and not necessarily patho-
logical. Under certain disease conditions, however,
coronary constriction becomes more dominant than
in the healthy population and may contribute to
symptoms such as angina pectoris [19]. The degree
of coronary constriction may differ considerably in
different syndromes and different patients. Indeed,
in certain patients coronary constriction may be
only slightly increased and hence no symptoms may
occur at rest; however, the increased coronary tone
may signiﬁcantly alter the threshold for angina
during exercise in these patients [20,21]. On the
other hand, coronary constriction may be so severe
that myocardial ischemia occurs even at rest in
some patients with angiographically normal coro-
nary arteries. Under such conditions, a near-total
or total occlusion, or severe diffuse constriction
of the coronary artery can be demonstrated. Some
authors have emphasized the difference between
increased constriction and total occlusion of a
coronary artery and have restricted the expres-
sion ‘‘coronary spasm’’ to the latter condition
[22]. However, increased constriction contributes
to a various spectrum of ischemic heart disease
and the same patients may have different degree
of coronary constriction at different times. Thus,
the difference between hyperconstriction and total
occlusion is gradual and the distinction between
coronary spasm and hyperconstriction is artiﬁcial
[19,23]. Indeed, hyperconstriction usually involves
the entire coronary artery, although the degree
of constriction may differ among segments of
the artery, resulting in total occlusion in some
cases.
We deﬁne coronary spasm as an abnormal con-
traction of an epicardial coronary artery resulting
in myocardial ischemia [14,18]. With this deﬁni-
tion, there are no limits on the degree of lumen
diameter reduction required to diagnose coronary
b
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pasm since ischemia must accompany the changes
f vessel size.
revalence of coronary spasm
here are not enough data on the prevalence of
oronary spasm both in the Eastern and Western
ountries, probably because it is difﬁcult to exam-
ne coronary spasm systematically at the each time
f coronary angiography. The prevalence rate may
lso vary depending on the interest and eager-
ess on the part of the investigators. Bertrand and
o-workers reported in 1982 that coronary spasm
as provoked by ergonovine in 20% of patients
ith recent myocardial infarction and in 15% of
atients who complained of chest pain in 1089 con-
ecutive patients undergoing coronary angiography
24]. Coronary spasm has become less frequent
n the Western countries recently. This is prob-
bly due to the facts that Ca-channel blockers
CCBs), which are speciﬁcally effective in sup-
ressing coronary spasm, have been widely used
or chest pain and/or hypertension, and/or better
itrate regimens have been developed and used.
lso, many cardiologists are now not much inter-
sted in coronary spasm and provocation tests for
t are less often performed [25]. Coronary spasm
s, however, still prevalent and provocation tests
or it are routinely performed at many institu-
ions in Japan [26] and perhaps in Korea [27].
he recent survey on the prevalence of coronary
pasm at multi-institutions in Japan showed that
oronary spasm was documented in 921 (40.9%)
f the 2251 consecutive patients with angina pec-
oris who underwent coronary angiography [26].
hus, there seems to be a racial difference in
he prevalence of coronary spasm between the
apanese and Caucasians. Indeed, a recent report
howed a major racial difference in coronary con-
trictor response between Japanese and Caucasians
28]. However, the frequency has become less
requent also in Japan probably because of the
revalent use of CCBs for hypertension as well as
or ischemic heart disease and the decreased inci-
ence of smokers [29]. Increased medications of
spirin, statins, ACE inhibitors, or angiotensin II
eceptor blockers may also have contributed to
he reduction of coronary spasm [30]. It is also
ossible that cardiologists now may be more inter-
sted in patients who are in need of percutaneous
oronary intervention (PCI) and do not want to be
othered with coronary spasm. Many cardiologists
onsider the provocation test for coronary spasm
oo cumbersome and time-consuming for the busy
nvasive-interventional laboratory and think that a
Coronary artery spasm
Figure 1 Diurnal distribution of the ischemic episodes
in patients with variant angina. The attacks occur most
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tften from midnight to early morning. To be noted is that
he number of asymptomatic attacks was larger than that
f symptomatic attacks. (From Yasue and Kugiyama [18].)
rial of CCBs may be enough for the evaluation of
ossible spasm [18].
linical manifestations
ircadian variation
oronary spasm occurs usually at rest, particu-
arly from midnight to early morning [6,12—19]
Fig. 1). Although Prinzmetal et al. [6] empha-
ized that variant angina is not induced by exercise,
oronary spasm can often be induced even by
ild exercise in the early morning [20,31]. How-
ver, it is usually not induced in the afternoon
ven by strenuous exercise. Thus, there is a cir-
adian variation in the exercise capacity in the
atients with coronary spasm [20]. It is now known
hat the attacks of all forms of ischemic heart
isease including acute myocardial infarction and
udden death occur most often in the early morn-
ng [13,17,18,32]. This may be related at least
artially to the fact that the tone of an epi-
ardial coronary artery is increased in the early
orning, whereas it is decreased in the afternoon
20].
The causes of the circadian variation of coronary
pasm remain to be elucidated. Because coronary
pasm can be induced by intracoronary injection
f acetylcholine (ACh) [33], the neurotransmitter
f the parasympathetic nervous system, changes in
he activity of the autonomic nervous system may
e involved in the circadian variation of coronary
pasm [34]. Coronary spasm can also be induced
y stimulation of alpha-adrenergic receptors [10].
ircadian variations of the production of various
ormones including cortisol, vasopressin, mela-
onin, growth hormone, and insulin or inﬂammatory
ytokines including TNF-alpha or IL-1, may also
T
t
i
c5
e related to the circadian variation of coronary
pasm.
ymptoms and the ECG changes
he commonly associated manifestations of
yocardial ischemia due to coronary spasm are
hest pain and ST segment changes on the ECG.
hest pain is similar in quality to that of stable
ffort angina, but is often more severe and pro-
onged, accompanied by cold sweat, nausea or
omiting, and sometimes by syncope. It should
e noted, however, that myocardial ischemia due
o coronary spasm often occurs without accom-
anying symptoms [18,34]. Indeed, the incidence
f silent myocardial ischemia caused by coronary
pasm is more than two times higher than that of
ymptomatic ischemia (Fig. 1) [18].
The ECG changes that occur during the attack
f coronary spasm include ST segment elevation
nd/or depression, peaking and/or increase in
mplitude of the T wave, a delay in the peak and
n increase in the height and width of the R wave
esulting in fusion of R wave with T wave, and a
ecrease in magnitude or disappearance of the S
ave. The negative U wave may also appear at
he beginning or near the end of the attack, and
s often associated with ST segment changes in the
nterolateral leads. It may be the only ECG change
hat occurs during a mild attack when spasm is
ess severe and does not cause the total obstruc-
ion of a coronary artery. Total or subtotal occlusion
f a major coronary artery by spasm, results in ST
egment elevation in the leads that represent the
rea of myocardium supplied by the artery. The
T segment elevation is usually accompanied by
eciprocal ST segment depression in the opposite
eads. It is therefore important to record electro-
ardiograms in multiple leads. The magnitude of ST
egment elevation varies and corresponds roughly
o the degree of acute myocardial ischemia. As the
ttack proceeds, the magnitude of ST segment ele-
ation increases and, in association with an increase
n magnitude and widening of the R wave in the
ame lead, may form a ‘‘monophasic curve’’ at the
eak of the attack. This ‘‘monophasic curve’’ is
sually not seen during the attack of acute myocar-
ial infarction and is characteristic of a severe
ttack of coronary spasm occluding the proximal
egment of a major coronary artery. The ST seg-
ent elevation appears in the leads corresponding
o the distribution of one major coronary artery.
he leads in which ST segment appears are usually
he same during each attack in the same patient,
ndicating that spasm usually appears at the same
oronary artery in the same patient. However, it is
6 H. Yasue et al.
Figure 2 The ECG changes during the attacks of multi-vessel coronary spasm. During the spontaneous attack, ST
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Tsegment elevation appeared in the chest leads (leads V2—
II, and aVF). During the attack induced by exercise, ST s
leads (leads II, III, aVF, and V2—4). Ventricular tachycardia
not rare that ST segment elevation occurs in the
anterior leads during one attack and in the inferior
leads in another in the same patients. There are
also patients in whom ST segment elevation occurs
simultaneously both in the anterior and inferior
leads (Fig. 2). These are patients with simultaneous
multi-vessel coronary spasm and the attacks often
result in ventricular tachycardia and/or ﬁbrillation
(Fig. 2) [17,18,35]. There is not much difference in
the incidence of ST segment elevation between the
anterior leads and inferior leads. The ECG may be
unchanged at the beginning of an attack or when
the attack is mild. Occasionally, pseudonormaliza-
tion of a previously depressed ST segment may
appear.
Coronary spasm may also cause ST segment
depression instead of elevation in the leads that
represent the distribution area of the spasm artery.
The ST segment depression indicates less severe
(non-transmural or sub endocardial) myocardial
ischemia than does ST segment elevation, which
represents transmural myocardial ischemia. The ST
segment depression occurs: when (1) spasm of a
major artery is less severe (subtotal and/or diffuse;
a
s
t
And ST segment depression in the inferior leads (leads II,
nt elevation appeared in both the anterior and inferior
appeared during the attack as shown at the bottom.
2) a major artery receiving collaterals is com-
letely occluded; or (3) a small artery is completely
ccluded [23]. The direction and extent of ST seg-
ent change may vary from one episode to another
nd that ST segment elevation and depression can
ccur in the same patient or even in the same lead
ithin minutes or hours [15].
Various forms of arrhythmia often appear dur-
ng attacks of coronary spasm associated with
T segment elevation. These include ventricu-
ar arrhythmias such as ventricular premature
ontractions or ventricular tachycardia, brad-
arrhythmias, atrioventricular block, and supraven-
ricular arrhythmias. Ventricular ﬁbrillation may
lso appear rarely.
Ventricular arrhythmias appear more often when
T segment elevation occurs in the anterior leads.
radyarrhythmias appear more frequently when ST
egment elevation occurs in the inferior leads.
he high-degrees of bradyarrhythmias are often
ssociated with hypotension, and sometimes with
yncope. Lethal arrhythmias such as ventricular
achycardia, ventricular ﬁbrillation and complete
V blockmay appear particularly during an attack of
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ulti-vessel spasm (Fig. 2) [17,18,35,36]. There is a
ood correlation between the incidence of arrhyth-
ia and the degree of ST segment elevation).
oronary angiographic and hemodynamic
hanges
oronary spasm has been thought to occur at a site
f organic stenosis of a major coronary artery [6].
owever, coronary spasm appears in angiographi-
ally normal arteries as well as those with organic
tenosis [18,36—38]. Of the 179 patients with coro-
ary spasm at our institution [18], 126 (70%) had
ormal or near normal coronary arteries. Spasm
ay be diffuse or diffuse plus focal [39] and may
ven migrate from site to site. Spasm occurs not
nly at one large coronary artery but also at two or
hree large arteries separately or simultaneously in
he same patients. Multi-vessel spasm was demon-
trated in 93 (52%) of the patients (Fig. 3) and 77
83%) of these patients had normal or near-normal
oronary arteries [18].
The patients with multi-vessel coronary spasm
ave the following characteristics: (1) most of them
r
d
t
a
igure 3 Coronary angiograms in a patient with multi-vesse
he left coronary artery (top left) and the right coronary ar
eparately. Please note that spasm appeared in all three m
ircumﬂex artery and right coronary artery). Spasm was reve
ISDN, top right and bottom right). There was no signiﬁcant o7
ave angiographically normal coronary arteries; (2)
hey are resistant to treatment and often require
arger amounts of CCBs to suppress the attacks,
hich often recur on cessation of the drugs; (3)
hey are more likely to have lethal arrhythmias such
s ventricular tachycardia or ventricular ﬁbrillation
nd are more likely to suffer from sudden death
18].
There is no consistent increase in heart rate,
lood pressure or dP/dt before the onset of ST
egment elevation. The most typical and early
emodynamic pattern observed in the initial phase
f coronary spasm is a reduction of positive and neg-
tive peak dP/dt and elevation of endo-diastolic
ressure of the left ventricle [15]. These hemo-
ynamic changes occur before the appearance of
T segment elevation. Subjective symptoms always
ollow ST segment and hemodynamic changes.
yocardial ischemia alters not only the contractile
roperties of the heart, but also impairs ventricular
elaxation. The combination of incomplete myocar-
ial relaxation and depressed contractility leads
o elevated ventricular ﬁlling pressure. Thus, the
ppearance of wall motion abnormalities is the
l coronary spasm. Injection of acetylcholine (ACh) into
tery (bottom left) induced spasm in each of the artery
ajor arteries (the left anterior descending artery, left
rsed after intracoronary injection of isosorbide dinitrate
rganic stenosis in the arteries.
H. Yasue et al.
Figure 4 Circadian variation of plasma levels of ﬁbri-
bopeptide A in patients with variant angina and those
with stable exertional angina. Plasma levels of ﬁb-
rinopeptide A are increased and show marked circadian
variation with a peak appearing from midnight to early
morning in patients with variant angina. In contrast, the
levels are not increased and do not show a circadian vari-
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most sensitive marker of myocardial ischemia and
this can easily be detected by echocardiograms
[27,40,41]. The appearance of wall motion abnor-
malities of the left ventricle during the attack has
also been demonstrated by ventriculography [11].
Precipitating factors
There are several factors which may precipitate
coronary spasm. These may be divided into phys-
iological factors and pharmacological agents.
Coronary spasm occurs most often at rest, par-
ticularly from midnight to early morning. However,
in the early morning, even mild exertion may
induce coronary spasm [18]. Physical and/or men-
tal stress, particularly the latter, for several weeks
or months may precipitate coronary spasm, par-
ticularly at rest [18,42]. Exposure to cold [43],
Valsalva maneuver and hyperventilation [40,44—46]
may also precipitate coronary spasm. Magnesium
deﬁciency is also associated with coronary spasm
[46,47]. Coronary spasm itself often induces coro-
nary spasm, thus making vicious circle [18].
Pharmacological agents include catecholamines
(epinephrine, norepinephrine, isoproterenol,
dopamine, dobutamine) [10,48,49] parasympath-
omimetic agents (acetylcholine, methacholine,
pilocarpine) [33,34], anticholinesterase agents
(neostigmine, etc.) [50], ergonovine [27,51—53],
serotonin [54], histamine [55], beta-adrenergic
blocking agents [34,56], withdrawal from chronic
exposure to nitroglycerin [57], cocaine [58], smok-
ing [59,60], and alcohol [61,62]. Particularly to be
noted in the daily life is alcohol ingestion. Heavy
drinking after stressful situations often induces
coronary spasm, usually not immediately but after
several hours when blood levels of alcohol may
have disappeared.
These factors or agents may induce coronary
spasm singly. However, when several of these fac-
tors are combined, the possibility of occurrence of
coronary spasm is high [18].
Coronary spasm and coronary thrombosis
Coronary thrombosis is now known to be the
cause of acute coronary syndromes including
acute myocardial infarction, unstable angina and
ischemic sudden death [63—65]. Coronary spasm
may also be involved in the pathogenesis of acute
coronary syndromes [15—18]. Plasma levels of ﬁb-
rinopeptide A, a marker of thrombin generation,
are increased after attacks of coronary spasm
[66,67] and there is a circadian variation in the lev-
els in parallel with that of the attacks of coronary
spasm (Fig. 4) [67]. Plasma levels of plasmino-
s
c
ation in patients with stable exertional angina. p < 0.05,
*p < 0.01, difference of the levels between patients with
ariant angina and those with stable effort angina at each
ampling time. (From Ogawa et al. [67].)
en activator inhibitor 1 also show a circadian
ariation in parallel with that of the attacks of coro-
ary spasm [68]. Platelets also are activated after
ttacks of coronary spasm but not after those of sta-
le effort angina [69]. These ﬁndings indicate that
oronary spasm can trigger coronary thrombosis
nd may play an important role in the pathogene-
is of acute coronary syndromes. Indeed, coronary
hrombosis has been demonstrated by angioscopy
n patients with variant angina [70].
iagnosis of coronary spasm
he diagnosis of coronary spasm is not necessarily
asy. In contrast to stable effort angina, which is
eproducibly induced by exercise testing, coronary
pastic angina is usually not induced by exercise,
articularly in the afternoon and occurs usually at
est, particularly from midnight to early morning
18,20]. The attack is transient, often lasts only
few seconds, and is unpredictable. Thus, ambu-
atory monitoring of ECG is extremely important
o detect the attack [13,18]. However, even with
mbulatory monitoring of ECG, the attack may not
ppear during the monitoring periods, especially
hen the attack is not frequent. Moreover, ECG
oes not provide a direct evidence of coronary
pasm.
It is for these reasons that provocation tests for
oronary spasm have been developed. These afford
n opportunity to induce an episode of coronary
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Coronary artery spasm
pasm at a chosen time, when the patient is ade-
uately monitored in a laboratory well equipped for
ppropriate documentation of this phenomenon.
everal provocative tests for coronary spasm have
een developed. Of these ACh and ergonovine tests
re most often used [24,27,33,36,51—53]. Coronary
rteries involved in spasm are super-sensitive to
Ch and ergonovine. Ergonovine is an ergot alkaloid
hat stimulates both alpha-adrenergic and sero-
onergic receptors and the intracoronary injection
f doses ranging from 10 to 80g in total are
sed at most institutions. However, spasm involv-
ng both the right and left coronary artery may
ot be demonstrated with this route of administra-
ion, because nitroglycerin must be administered to
elieve spasm after its demonstration in the infused
rtery and spasm cannot be provoked in the other
emaining artery.
The intracoronary injection of ACh in doses
f 10—100g is used for provocation of coronary
pasm [33,36]. Duration of the action of injected
Ch is very short and the induced spasm usually
isappears spontaneously within 2—3min without
he need of nitrates administration. Thus, this
ethod allows provocation of spasm separately in
he left and right coronary arteries and is useful
o demonstrate multi-vessel spasm (Fig. 3) [36].
he intracoronary injection of ACh into the right
oronary artery often induces bradyarrhythmias,
articularly and insertion of a standby temporal
acemaker is obligatory.
Coronary spasm can also be induced by hyperven-
ilation, which causes respiratory alkalosis [44—46].
he sensitivity of this test is 65% and the speci-
city is 100% [45]. It may thus be safely said that
oronary spasm exists when an ischemic attack is
nduced by hyperventilation. However, there is a
anger of inducing simultaneous multi-vessel spasm
ith this method of provocation. Histamine [55],
pinephrine [10], dopamine [48], dobutamine [49],
erotonin [54], exercise in the morning [20,31], and
he cold pressor test [43] can all induce coronary
pasm, but all of these tests is less sensitive than
rgonovine or ACh.
There are daily, monthly and yearly as well as
ircadian variations in the attack of coronary spasm
13,18] and the sensitivity of the tests depends on
he disease activity of the time. Thus, a false neg-
tive test may often be obtained in patients with
stablished coronary spasm when the disease activ-
ty is low.
Although the provocation tests for coronary
pasm by ACh or ergonovine are usually safe, a
umber of complications may occur. These include
arious arrhythmias, hypertension, hypotension,
bdominal cramps, nausea, vomiting, and other
c
i
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i9
on-speciﬁc complications. Rarely, serious compli-
ations such as ventricular ﬁbrillation, myocardial
nfarction, or even death may occur [17,35].
herefore, the tests should be conducted only by
ualiﬁed physicians and in a setting where appropri-
te resuscitation and other measures can promptly
e done.
Strictly speaking, the diagnosis of coronary
pasm must be made on the basis of coronary angio-
raphic ﬁndings during the attack. However, it is
ot possible to perform coronary angiography dur-
ng the attack in every patient and there is no need
or this.
Angina pectoris that is relieved promptly by
ublingual administration of nitroglycerin may be
iagnosed as coronary spastic angina even without
ngiographic evidence, if one of the following char-
cteristics is found.
These characteristics are:
. The attack occurs at rest, particularly from mid-
night to early morning.
. There is marked circadian variation of exercise
capacity, the attack easily induced by exercise
in the morning but not by even vigorous exercise
in the afternoon.
. The attack is associated with ST segment eleva-
tion on the ECG.
. The attack is induced by hyperventilation.
. The attack is suppressed by CCBs, but not by
beta-blockers.
isk factors for coronary spasm
oronary spasm is mostly a disease of middle-
nd old-aged men and post-menopausal women
18,60]. The disease rarely occurs in the young men
nd pre-menopausal women. Age, LDL-cholesterol,
ypertension, diabetes mellitus, and smoking are
ll known to be a signiﬁcant risk factor for stable
ffort angina or coronary atherosclerosis [2,3,71].
n the other hand, age, smoking, high sensitivity
-reactive protein (hsCRP), and remnant lipopro-
eins are a signiﬁcant risk factor for coronary spasm
59,60,72—76]. The incidence of cigarette smoking
s signiﬁcantly higher among patients with coronary
pastic angina than among those with stable effort
ngina [59,60]. These facts suggest that the patho-
enesis of coronary spasm may differ from that of
oronary atherosclerosis, which is closely related
o abnormalities of LDL-cholesterol metabolism.
igarette smoking is thus, a crucial risk factor for
oronary spasm and highlights the fact that the high
ncidence of cigarette smoking may be one of the
actors for the high prevalence of coronary spasm
n the Japanese.
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In addition to cigarette smoking and other envi-
ronmental factors, genetic factors may also be
involved in the pathogenesis of coronary spasm as
will be described in the next section.
Pathogenesis of coronary spasm
The exact mechanisms by which coronary spasm
occurs remain to be elucidated.
The endothelial dysfunction and oxidative
stress
The vascular endothelium was once thought as a
simple passive barrier between circulating blood
and surrounding tissues. However, recent evidence
indicates that it is a multifunctional organ the
integrity of which is essential to normal vascular
physiology, and its dysfunction can be critical for
the pathogenesis of vascular disease [77].
ACh causes vasodilation by releasing nitric
oxide (NO) from the endothelium and in humans,
intracoronary infusion of ACh induces coronary
vasodilation in young healthy subjects, whereas
it causes vasoconstriction in patients with coro-
nary atherosclerosis [77—79]. Coronary arteries in
patients with coronary spastic angina are highly
sensitive to the vasoconstrictor effect of intra-
coronary injection of ACh, resulting in spasm
[33,36]. Intracoronary injection of ACh is thus
used as a provocative test for coronary spasm
[33,36]. Coronary spasm can also be induced by
ergonovine, serotonin, or histamine, all of which
are endothelium-dependent vasodilators by releas-
ing NO.
On the other hand, nitrates including nitroglyc-
erin, are endothelium-independent vasodilators
and cause vasodilation by being converted into NO
in vivo, which stimulates soluble guanylate cyclase,
resulting in increased cyclic GMP [79,80]. The coro-
nary arteries in patients with coronary spasm are
highly sensitive to the vasodilator effect of nitrates
[39,81]. It is thus possible that super-sensitivity of
spasm arteries to nitroglycerin is due to the deﬁ-
ciency of endogenous NO activity in these arteries
[80—86].
NO is synthesized from L-arginine by way of
NO synthase (NOS) and NO synthesis is speciﬁ-
cally blocked by L-monomethyl-arginine (L-NMMA)
[79,80]. The coronary artery diameter decreases in
response to intracoronary infusion of L-NMMA in the
control subjects, whereas it does not change signif-
icantly in patients with coronary spasm [84]. These
observations indicate that NO is released in the
basal state and is involved in the regulation of basal
c
e
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ascular tone in normal humans and that NO activity
s deﬁcient in the coronary artery in patients with
oronary spasm. There is a signiﬁcant positive cor-
elation between the response to L-NMMA and that
o nitroglycerin, i.e. the smaller the response to
-NMMA, the larger the response to nitroglycerin,
ndicating that the super-sensitivity to nitroglyc-
rin is related to the deﬁciency of endogenous NO
ctivity in the coronary artery in patients with coro-
ary spasm [81,85]. NO-mediated ﬂow dependent
ilation is also impaired in patients with coronary
pasm [86].
NO is also known to suppress the production
f endothelin 1 and angiotensin II which are
otent vasoconstrictors and proliferators of vas-
ular smooth muscle and deﬁciency of NO may
nhance the synthesis of these potent vasoconstric-
ors [87,88]. Indeed, there are intimal thickening
nd hyperplasia in the coronary arteries involved in
pasm [89,90].
The deﬁciency of NO activity may be due to
ither a decrease in production or an increase in
egradation of NO before it can produce its effect
n smooth muscle, or both.
olymorphisms of eNOS gene
ndothelial NO is synthesized by endothelial NOS
e-NOS) which is constitutively expressed in the
ndothelium [79]. We have recently found the poly-
orphisms of Glu298Asp in the exon 7 and T−786C
n the 5′-ﬂanking region of the e-NOS gene and
ave shown that these polymorphisms are signif-
cantly associated with coronary spasm [91,92].
hese ﬁndings strongly suggest that the e-NOS
ene polymorphisms compromise the endothelial
O production and predispose the patients with
hese alleles to coronary spasm. Further more,
ot only coronary arteries but also the peripheral
rteries are deﬁcient in NO activity in patients
ith coronary spasm [93—95], suggesting that
eﬁciency of NO activity may occur not only
n the coronary arteries but also in the entire
ascular system in these patients. However, NO
olymorphisms are found in only one-third of the
atients and thus other genes or factors may
lso be involved in the pathogenesis of coronary
pasm.
xidative stress
xygen free radicals degrade NO and cause vaso-
onstriction [79,80]. Both basal and ACh-induced
ndothelial dysfunction in coronary arteries are
mproved by intracoronary injection of antioxidants
uch as vitamin C or glutathione, in patients with
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Roronary artery spasm
oronary spasm [96—98]. Plasma levels of vita-
in E, another antioxidant, are low and those of
hioredoxin, a marker of oxygen species, are high
n patients with coronary spastic angina [99—101].
oronary spasm rarely occurs in pre-menopausal
omen except those who smoke [18] and estro-
ens have antioxidant activity and suppress the
ttack in post-menopausal women with coronary
pastic angina [102]. Interestingly, there is a men-
trual cyclic variation of the attack in association
ith changes of plasma levels of estrogen in pre-
enopausal women with coronary spastic angina
103]. Coronary spasm is signiﬁcantly associated
lso with polymorphism of the gene for paraox-
nase I, which has an antioxidant effect [104] and
he plasma level of thioredoxin, a marker of oxida-
ive stress, is increased in patients with coronary
pasm [101]. Coronary spasm is more prevalent
mong smokers than in non-smokers [59,60] and
ndothelial function is impaired both in coronary
nd brachial arteries and is improved by vitamin
infusion in smokers [105,106]. Cigarette smoke
xtract markedly suppresses the ACh induced
ndothelium-dependent relaxation and the sup-
ression is prevented by antioxidants in isolated
rteries [107,108]. All of these ﬁndings indicate
hat smoking degrades NO by way of oxygen rad-
cals.
Multiple regression analysis reveals that smoking
s well as e-NOS and paraoxonase I polymorphisms
s a highly signiﬁcant risk factor for coronary spasm
59,60,91,92,104]. Increased NO degradation by
xygen radicals or both may play an important role
n the pathogenesis of coronary spasm.
However, there are still some controversies
egarding endothelial dysfunction in patients with
oronary spasm and some workers report that there
s no endothelial NO deﬁciency and dysfunction in
atients with coronary spasm [109].
hronic low-grade Inﬂammation
himokawa and his coworkers [110] has developed
he swine mode of coronary spasm by chronically
pplying IL- to the coronary artery of the animal.
dhesion-molecule such as P-selection is increased
n the coronary artery involved in spasm [111].
lasma levels of hsCRP, a sensitive marker of inﬂam-
ation, are also increased in patients with coronary
pasm as compared with those of non-coronary
pasm patients [72,73]. Chronic smoking, a number
ne risk factor for coronary spasm, is associated
ith chronic low-grade inﬂammation [112]. These
ndings indicate that chronic low-grade inﬂamma-
ion plays an important role in the pathogenesis of
oronary spasm.
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ypercontractility of coronary smooth
uscle
ontraction and relaxation of vascular smooth mus-
le are regulated by myosin light chain (MLC) kinase
MLCK) and myosin light chain phosphatase (MLCP)
hrough phosphorylation and dephosphorylation of
LC [113]. The classical pathway through which
ontracting stimuli induce MLC phosphorylation is
n increase of the free intracellular Ca2+ concen-
ration. The complex of Ca2+ and calmodulin then
ctivates MLCK, leading to increased MLC phospho-
ylation [114]. Coronary spasm may be regarded as
yper-contraction of coronary smooth muscle trig-
ered by an increase of intracellular Ca2+ and CCBs,
hich block the entry of Ca2+ into cells, are highly
ffective in suppressing coronary spasm [14,31,53].
It has recently shown that Ca2+-independent
egulation also occurs through the inhibition of
LCP and that the level of MLC phosphoryla-
ion is determined by a balance between MLC
hosphorylation by MLCK and dephosphorylation
y MLCP [115—119]. Accumulating evidence indi-
ates that small GTPase RhoA and its downstream
ffector, ROCK/Rho-kinase, inhibit MLCP, leading
o augmentation of MLC phosphorylation and Ca2+
ensitization in response to vasoconstrictor stim-
li. Studies showed that RhoA/ROCK activity is
nhanced in the rat arteries with hypertension and
asospasm [115—119].
Shimokawa and colleagues [110,119] have devel-
ped swine models of coronary spasm and have
hown that ROCK activity is enhanced in smooth
uscles of the coronary artery involved in spasm
n these animals. They also showed that spe-
iﬁc inhibitors of ROCK relieved coronary spasm
n humans [120]. Statins, which block the RhoA/
OCK pathway [121], also suppress coronary spasm
122]. It is thus quite probable that enhanced
a2+ sensitization via enhanced Rho/ROCK activ-
ty as well as increased intracellular Ca2+ may play
critical role in the genesis of coronary spasm.
he precise mechanisms by which the activity of
ho/ROCK pathway is increased remain to be eluci-
ated. Recent studies show that cGMP-dependent
rotein kinase inhibits RhoA-induced Ca2+ sensiti-
ation of contraction in vascular smooth muscle
123,124]. Decreased endothelial NO activity has
een shown to increase Rho/ROCK activity in the
oronary arteries [119,124—127].
These new ﬁndings thus, connect the activity of
hoA/ROCK to endothelial NO and are in agreement
ith the clinical observations that spasm arteries
re super-sensitive to both vasoconstrictor ago-
ists and nitrates [39,83]. Enhanced phospholipase
activity may also be involved in coronary spasm
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through enhanced contraction of vascular smooth
muscle cells [128,129].
Magnesium
Magnesium is said to be an endogenous calcium
antagonist, and infusion of magnesium suppresses
hyperventilation-induced attack in patients with
coronary spasm [46]. There is magnesium deﬁciency
in 45% of the patients with variant angina and
magnesium deﬁciency may be related to the gen-
esis of coronary spasm in some of the patients
[47,62].
Treatment
Acute attack
The attack of coronary spasm can usually be
promptly relieved by the sublingual administration
or oral spray of nitroglycerin or isosorbide dinitrate
(ISDN). In refractory spasm, intravenous or intra-
coronary injection of the drugs may be necessary.
Nitrates are converted in vivo to NO [79,80] and the
administration of nitrates may be regarded to be a
replacement therapy for deﬁciency of endogenous
endothelial NO in patients with coronary spasm.
Indeed, coronary arteries involved in spasm are
highly sensitive to nitrates [39,82,83].
Prevention of coronary spasm
Though the sublingual administration of nitro-
glycerin or ISDN rapidly relieves the attack, the
duration of actions of these drugs is short and
less than an hour. For the prevention of attack,
long-acting drugs are needed and CCBs are very
effective for this purpose. CCBs inhibit inﬂow
of Ca2+ into the smooth muscle cell through
voltage-sensitive Ca2+ channels, thereby causing
vasodilation [18]. The efﬁcacy of these drugs
against the attack of coronary spasm is often
dramatic.
It is to be noted that timing of the administra-
tion of these drugs is important because the attacks
of coronary spasm usually occur from midnight to
early morning. These drugs should then be given
before going to bed in the night. Doses should also
be gradually increased in the individual patient,
paying due attention to the side effects. In patients
with multi-vessel coronary spasm, CCBs should not
be withdrawn even if the symptomatic attacks
occur rarely because silent myocardial ischemia
often occurs [18] and there is a danger of sud-
den death from lethal arrhythmias in these patients
[17,18,35].
l
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Long-acting nitrates (oral or transdermal) are
lso useful for preventing coronary spasm. How-
ver, the potency of nitrates is reduced by nitrate
olerance [130—132]. In the clinical practice, inter-
ittent therapy with a nitrate-free window of at
east 8 h has been recommended. Nicorandil, a
itrate and K-channel activator, is also effective in
uppressing coronary spasm [133].
For refractory coronary spasm, larger doses
nd combination of different classes of CCBs,
ogether with nitrates may be necessary. In addi-
ion, magnesium [46], statins [122], antioxidants
uch as vitamin C and E, ACE-inhibitors, ARBs,
nti-inﬂammatory agents as aspirin, or estrogen in
ost-menopausal women, may also have beneﬁcial
ffects on coronary spasm [94,96—100]. Because
ontraction of vascular smooth muscle is under the
ual control of intracellular Ca2+ and RhoA/ROCK
ctivity, inhibitors of RhoA/ ROCK pathway may
lso prove useful for the treatment and prevention
f coronary spasm in the future [119—122]. There
re, however, some patients with coronary spasm
hose attacks are refractory to and cannot be
ompletely controlled even by these medications
17,18].
eneral measures
ecause patients with coronary spasm have
ndothelial dysfunction [82,84], the elimination or
ontrol of the factors which may impair endothelial
unction or increase oxidative stress, particu-
arly smoking, is very important. Thus, elimination
r control of all the risk factors for coronary
therosclerosis [2,71], is also necessary in the
ase of coronary spasm. Drinking alcohol may
nduce attacks of coronary spasm usually not
mmediately but several hours after drinking in
usceptible patients [61]. Strenuous exercise in
he daytime may also induce the attacks in the
idnight or in the early morning [18]. Emotional
tress is a very important substratum for the
ttacks and anger or fear may induce the attacks.
he attacks often disappear without any medica-
ions by hospitalization alone probably because the
atients are shielded from social stress. Magne-
ium, which is an endogenous calcium antagonist,
ust be supplied in the patients deﬁcient in this
lement [46,47,62]. Drugs that may induce coro-
ary spasm must be avoided. Such drugs include
atecholamines, muscarinic agonists, ergot alka-
oids, prostaglandins, alcohol and propranolol. In
ost-menopausal women with refractory coronary
pasm, estrogen replacement therapy may be use-
ul [102].
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Roronary artery spasm
rognosis
he natural history of variant angina or coronary
pasm is generally characterized by periods of
ecurrent attacks lasting for 3—6 months alter-
ating with the periods in which the patient is
symptomatic. Long-term survival is usually good
o long as patients are on CCBs and avoid smoking
134—137].
The predictors for prognosis are the num-
er of coronary artery with signiﬁcant organic
tenosis, medication of CCBs and multi-vessel
oronary spasm [135]. In many patients, the
ttack tends to diminish with time after a few
onths of recurrent attacks. There is still no
eﬁnite answer as to how long the adminis-
ration of CCBs should be continued. It is our
pinion that patients with multivessel patients
hould be on CCBs indeﬁnitely because these
atients often have lethal arrhythmias (ventricular
achycardia, ventricular ﬁbrillation, high-degree AV
lock, or asystole) and are at high risk of sud-
en death [17,18,35,36], even though they may
e asymptomatic. They also require high doses
f CCBs to suppress the attacks. They should be
losely watched and followed by a knowledgeable
hysician.
linical perspective
he incidence of coronary spasm seems to be
ecreasing throughout the world, including Japan,
robably because of the wide use of medica-
ions such as CCBs, statins, ACE-inhibitors, ARBs,
nd aspirin for cardiovascular disease [29]. The
ecreasing of smoking habit also may have con-
ributed to the reduced incidence of coronary
pasm. Many cardiologists, particularly the young,
re now much interested in PCI and pay less atten-
ion to coronary spasm. Multi-detector computed
omography scan are increasingly applied for evalu-
tion of coronary heart disease in place of coronary
ngiography. Under these circumstances, it is pos-
ible that there will be less and less cardiologists
ho are familiar with coronary spasm in the future.
ecause there are not a few patients with coronary
pasm who are refractory to the conventional medi-
ations and who may suffer from lethal arrhythmias
r sudden death, and because PCI is not the right
nswer to the problem of coronary spasm [138], it
s quite important for every clinician to be alert
o the presence of coronary spasm, which may
e silent and lethal. Coronary spasm is a hyper-
ontraction of coronary smooth muscle triggered
y an increase of intracellular Ca2+ in the pres-13
nce of an increased Ca2+ sensitivity. It has been
hown that RhoA/ROCK pathway is involved in Ca2+
ensitivity and that the reduced endothelial NO
ctivity results in increased Ca2+ sensitivity through
nhanced RhoA/ROCK pathway. Accordingly, it is
ossible that, RhoA/ROCK pathway blockers includ-
ng statins or fasudil may prove to be useful in
ddition to CCBs for the treatment of coronary
pasm [119,121]. Further studies are required to
lucidate the pathogenesis of this intriguing dis-
ase of coronary artery and developmore effective,
isease-modifying, and long-lasting treatments for
t.
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